Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The presentation by Dr. Aisen will take place at the Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. In his presentation entitled, A Phase III Study of the Efficacy, Safety and Disease Modification Effect of Tramiprosate in Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III clinical trial and provide an update.

Neurochem announced in April 2007 that an adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors, and Dr. Aisen will present on the progress to date. In addition, Dr. Aisen will provide an update on the progress in the analysis of the Phase III clinical trial primary endpoint data. Some preliminary descriptive data shows numerical differences in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and also shows differences between groups on the primary disease modification endpoint as measured by magnetic resonance imaging (MRI). However, work regarding the adjustment of the statistical model is ongoing and, therefore results of the Phase III clinical trial cannot be derived from the preliminary data nor can statistical significance be assigned at this time. Accordingly, no predictions or conclusions can yet be made regarding the outcome of the Phase III study.






Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:10/31/2014)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... quarter ended September 30, 2014. Brian ... third quarter was productive for Mast. Consistent with prior guidance, ... sickle cell disease is on track to complete enrollment ... 50 study sites in the U.S. and more than ...
(Date:10/31/2014)... Today, Analysts Review released its ... ), Bristol-Myers Squibb Co. (NYSE: BMY ), ... SA (NYSE: SNY ) and Actavis plc ... of publication. To reserve complementary membership, limited openings are ... Research Reports ,On October 23, 2014, Celgene Corporation (Celgene) ...
(Date:10/31/2014)...  Encision Inc. (OTCQB:ECIA), a medical device company owning ... in minimally invasive surgery, today announced financial results for ... The Company posted quarterly net revenue of ... thousand, or $(0.04) per share. These results compare to ... of $50 thousand, or $(0.01) per share, in the ...
Breaking Medicine Technology:Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5
... ATLANTA, July 18, 2011 Among the many new features ... with a simple way to deliver highly conformal stereotactic plans ... a target as the treatment beam rotates around the patient. ... Food and Drug Administration. "DCA can be used ...
... Caliper Life Sciences, Inc. (NASDAQ: CALP ... life science companies, today announced that Kevin Hrusovsky, President ... Stock Market Opening Bell on Tuesday, July 19th and ... customers to participate in this special event. This event ...
Cached Medicine Technology:New Release of Elekta's Monaco Treatment Planning System Prepares Software for Stereotactic Radiation Therapy 2Caliper Life Sciences to Ring The NASDAQ Stock Market Opening Bell on Tuesday, July 19 2Caliper Life Sciences to Ring The NASDAQ Stock Market Opening Bell on Tuesday, July 19 3
(Date:10/31/2014)... Energy Textiles has recently added a ... is now available online, and Energy Textile is providing ... infrared-active athletic gear over compression gear. , The ... been signed for Under Armour to provide team gear ... years. In light of this decision, Energy Textiles contemplates ...
(Date:10/31/2014)... (HealthDay News) -- Sleep apnea may make it hard for ... your car or left your house keys, a small study ... showed that this ability -- called spatial memory -- was ... even when other stages of sleep weren,t affected. REM sleep ... occur. "We,ve shown for the first time that sleep ...
(Date:10/31/2014)... duration of treatment and cost, patients with early ... breast irradiation (APBI) with proton therapy versus whole ... The University of Texas MD Anderson Proton Therapy ... study based on typical patient characteristics, researchers used ... eight different types of partial and whole breast ...
(Date:10/31/2014)... out of four older Americans say that either they ... medical treatment, according to the latest issue of The ... Report ( PP&AR ), which goes on to ... they fail to honor patients, end-of-life health care wishes. ... Care: Issues and Options ," features 12 articles that ...
(Date:10/31/2014)... Gold Medal Wine Club is making ... gifts for the wine novice and enthusiasts on their lists ... Special , which Early Bird shoppers receive discounts as high ... membership. , Gift Givers must place their orders before ... discounts, Gold Medal Wine Club adds more value to its ...
Breaking Medicine News(10 mins):Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Advance directives can benefit patients, families, and health care system 2Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2
... especially when the pollen count is high in the atmosphere. ... every year. In almost 38 million people, congestion and post ... infections. Newer treatments are now availble to combat such an ... Head and Neck Surgeon at , of Methodist Dallas Medical ...
... shows thickening of the heart may put young people at ... heart muscle protein // and is noticeable after the growth ... of breath on exertion, and a family history of sudden ... hypertrophic cardiomyopathy, can be seen on an electrocardiogram, but formal ...
... that overweight women might want to shed those extra pounds ... to // have a false-positive finding on a routine mammogram. ... those of normal weight to get breast cancer and also ... study exists on the accuracy of mammograms in overweight and ...
... but new research shows postmenopausal women who exercise have ... cholesterol levels. ,For the study researchers included 50 ... medications and had no diseases that affect bone metabolism. ... week for 26 months as well as two at-home ...
... fibrillation run a higher risk of stroke than those ... causes blood to pool, which can lead to a ... A new test to monitor people for irregular heartbeats ... ,Investigators evaluated about 150 patients who had just suffered ...
... world’s second leading cause of blindness. More than 66 ... research suggests doctors need to do more than just ... glaucoma. Researchers say examination of the optic nerve ... not someone has early stage glaucoma. ,Researchers say ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: